Candriam S.C.A. Purchases 7,063 Shares of Kenvue Inc. (NYSE:KVUE)

Candriam S.C.A. increased its position in Kenvue Inc. (NYSE:KVUE) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 112,627 shares of the company’s stock after purchasing an additional 7,063 shares during the quarter. Candriam S.C.A.’s holdings in Kenvue were worth $2,405,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of KVUE. State Street Corp raised its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares during the period. Holocene Advisors LP raised its holdings in shares of Kenvue by 75.5% in the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after purchasing an additional 5,975,392 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Kenvue in the 4th quarter valued at about $98,926,000. Finally, FMR LLC raised its holdings in shares of Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $23.46 on Monday. The company’s 50 day moving average price is $21.64 and its two-hundred day moving average price is $22.33. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market cap of $44.83 billion, a PE ratio of 44.25, a PEG ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue’s dividend payout ratio is 154.72%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on KVUE shares. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Barclays decreased their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.